Eupraxia Pharmaceuticals EPRX
NASDAQ EPRX
$8.06 +0.43 (+5.64%)
At close: Nov 11, 2026 · 4:00 PM EST

Eupraxia Pharmaceuticals (EPRX) Convertible Debt (2022 - 2024)

Updated

Eupraxia Pharmaceuticals (EPRX) reported Convertible Debt of $4.53 million for Q2 2024, down 52.2% from the prior quarter.

Analysis

Eupraxia Pharmaceuticals (EPRX) Convertible Debt (2022 - 2024) Analysis & Trends

At the end of FY2023, Eupraxia Pharmaceuticals posted Convertible Debt of $10.34 million, up 18.2% from FY2022.

  • By year, Convertible Debt came in at $8.74 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Eupraxia Pharmaceuticals 304.87 Mn -174.66 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 4.53 Mn
Mar 31, 2024 9.48 Mn
Dec 31, 2023 10.34 Mn
Dec 31, 2022 8.74 Mn
API Access

Eupraxia Pharmaceuticals Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=EPRX&period=max&api_key=YOUR_API_KEY